Drug Trial Radar · NCT04467983
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Feb 1, 2021
Primary completion
Sep 18, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Hospital for Special Surgery, New YorkAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Radius Health, Inc.; Crozer-Keystone Health System
- First posted
- Jul 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This randomized open label clinical trial will evaluate the effect of continued denosumab alone over 18 months versus denosumab with added abaloparatide for 18 months. 70 postmenopausal women will be enrolled over a period of 18 months. The co-primary outcomes will be group differences in bone mineral density (BMD) of the total hip and lumbar spine at 18 months. Secondary outcomes will include group differences in bone mineral density (BMD) at the femoral neck, trochanter and wrist sites at 6, 12 and 18 months, spine and total hip bone mineral density (BMD) at 6 and 12 months and trabecular bone score (TBS) at 18 months. Secondary outcomes will also include within group changes from baseline for each of these variables. Bone turnover markers will also be measured to demonstrate that PINP levels will increase with administration of abaloparatide even in the setting of ongoing denosumab, while CTX levels will remain low.
Conditions
- Osteoporosis, Postmenopausal
Interventions
Denosumab InjectionDrug
Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
AbaloparatideDrug
Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bone mineral density changes at total hip and lumbar spineTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital for Special Surgery
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.